MDT Earnings Date: Nov 17, 2026 (Estimated) — Medtronic Plc
NYSE · Healthcare · Medical Devices
Updated
When is MDT's next earnings date?
Medtronic Plc (MDT) is expected to report Q2 2027 earnings on Tuesday, November 17, 2026 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $1.33 on revenue of $9.48B.
How did MDT do in its last earnings report?
In its most recent report on Sep 1, 2026 (Q1 2027), Medtronic Plc posted EPS of $1.45 versus the $1.39 estimate, a beat of 4.3%. Revenue was $9.76B against a $9.55B estimate. The stock's 1-day post-earnings move was +1.5%.
How much does MDT stock move after earnings?
MDT beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 3.8% (up or down) in the day after earnings.
About Medtronic Plc
Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-01 | Q1 2027 | 1.39 | 1.45 | +4.32% | $9.76B | ✅ Beat | +1.53% | +1.92% | -4.23% |
| 2026-06-03 | Q4 2026 | 1.55 | 1.55 | +0.00% | $9.81B | ➖ Inline | +5.69% | +11.15% | +13.56% |
| 2026-02-17 | Q3 2026 | 1.33 | 1.36 | +2.26% | $9.02B | ✅ Beat | -3.09% | -0.88% | -11.11% |
| 2025-11-18 | Q2 2026 | 1.31 | 1.36 | +3.82% | $8.96B | ✅ Beat | +4.70% | +7.19% | +2.10% |
| 2025-08-19 | Q1 2026 | 1.23 | 1.26 | +2.44% | $8.58B | ✅ Beat | -3.14% | -0.83% | +1.90% |
| 2025-05-21 | Q4 2025 | 1.58 | 1.62 | — | $8.93B | ✅ Beat | -2.26% | -5.94% | -0.04% |
| 2025-02-18 | Q3 2025 | 1.36 | 1.39 | +2.21% | $8.29B | ✅ Beat | -7.26% | -2.84% | -0.64% |
| 2024-11-19 | Q2 2025 | 1.25 | 1.26 | +0.80% | $8.40B | ✅ Beat | -2.95% | -2.10% | -8.64% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q1 FY27 · $9.73B total
| Segment | Share | Revenue | YoY | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|---|---|---|
| Cardiac and Vascular Group | 40.4% | $3.93B | +19.5% | $3.10B | $3.04B | $3.33B | $3.29B |
| Neuroscience Group | 27.5% | $2.68B | +10.8% | $2.45B | $2.46B | $2.62B | $2.42B |
| Medical Surgical | 23.4% | $2.28B | +9.4% | $2.13B | $2.07B | $2.21B | $2.08B |
| Diabetes Group | 8.7% | $843.0M | +16.9% | $686.0M | $694.0M | $728.0M | $721.0M |
By region
Q1 FY27 · $24.22B total
| Segment | Share | Revenue | YoY | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 80.0% | $19.37B | +14.7% | $4.30B | $4.24B | $4.55B | $16.88B |
| Total Other Countries, Excluding United States and Ireland | 19.9% | $4.81B | +11.3% | $4.07B | $4.03B | $4.35B | $4.32B |
| IRELAND | 0.2% | $40.0M | +21.2% | $29.0M | $28.0M | $29.0M | $33.0M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.